Next Generation Drug Conjugates Market 2024

The next generation drug conjugates market size has grown rapidly in recent years. It will grow from $1.85 billion in 2023 to $2.15 billion in 2024 at a compound annual growth rate (CAGR) of 16%. The growth during the historic period can be attributed to a greater understanding of tumor biology, the success of early drug conjugates, a rise in oncology, increased investment and funding, and heightened patient advocacy and awareness.

The next generation drug conjugates market size is expected to see rapid growth in the next few years. It will grow to $3.91 billion in 2028 at a compound annual growth rate (CAGR) of 16.1%. The anticipated growth during the forecast period can be attributed to the expansion of combination therapies, an increase in clinical research, a focus on rare diseases, strategic collaborations, and the emergence of bioinformatics tools. Key trends in this period include advancements in monoclonal antibody technology, combination therapies involving JAK inhibitors, the application of artificial intelligence in drug development, the development of biosimilars, and innovations in subcutaneous formulations.

The increasing prevalence of cancer is anticipated to drive the growth of the next-generation drug conjugates market in the future. Cancer encompasses a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. The rise in cancer cases can be attributed to several factors, including an aging population, lifestyle choices, environmental exposures, advancements in detection, genetic predispositions, and infectious agents. Next-generation drug conjugates aim to combat cancer by delivering targeted therapies directly to cancer cells, thereby enhancing treatment effectiveness while minimizing harm to healthy tissues. For example, in August 2024, a report by the Australian Institute of Health and Welfare, a national agency focused on health and welfare statistics in Australia, projected that by 2034, the country would see approximately 209,000 new cancer diagnoses, up from an estimated 169,000 cases expected in 2024. This increase reflects the impact of a growing population and rising cancer rates. Hence, the escalating prevalence of cancer is propelling the growth of the next-generation drug conjugates market.

Key players in the next-generation drug conjugates market are pursuing strategic partnerships to enhance research and development capabilities, accelerate product innovation, and expand their market presence. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits and success. For instance, in November 2023, Prelude Therapeutics Incorporated, a U.S.-based clinical-stage precision oncology company, entered into a partnership with AbCellera Biologics Inc., a Canadian biotechnology firm, to develop first-in-class precision antibody-drug conjugates (ADCs) for oncology applications. This collaboration will focus on the discovery, development, and commercialization of innovative ADCs, beginning with a program targeting a SMARCA degrader linked to a novel antibody. The goal of this strategy is to expand the therapeutic applications of Prelude's small-molecule SMARCA2 selective degraders to a broader patient population, particularly those with cancers not associated with SMARCA4 mutations.

In March 2024, Johnson & Johnson, a U.S.-based pharmaceutical and medical device manufacturer, acquired Ambrx Biopharma for $2 billion. This acquisition aims to strengthen Johnson & Johnson's oncology portfolio and further the development of next-generation antibody-drug conjugates designed to transform cancer treatment. Ambrx Biopharma is a clinical-stage biopharmaceutical company in the U.S. specializing in next-generation drug conjugates.

Major companies operating in the next generation drug conjugates market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc., Tubulis GmbH.

North America was the largest region in the next generation drug conjugates market in 2023. The regions covered in the next generation drug conjugates marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the next generation drug conjugates marker report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Next-generation drug conjugates refer to advanced formulations designed to enhance the efficacy and safety of targeted therapies. These drug conjugates employ cutting-edge targeting technologies and improved payloads to deliver powerful treatments directly to disease cells with greater precision and fewer side effects.

The main types of next-generation drug conjugates include peptide receptor radionuclide therapy, ligand-mediated RNAi conjugates, ligand-conjugated antisense medicines, and peptide drug conjugates. Peptide Receptor Radionuclide Therapy (PRRT) is a targeted cancer treatment that utilizes radioactive peptides to bind to and destroy tumor cells that express specific receptors. The targeting ligands consist of amino sugars, lipids, peptides, small molecules, and virus-like particles, while the payloads include oligonucleotides, radionuclides, peptides, and small molecules. This therapy can be administered as either a monotherapy or in combination with other treatments for various indications, including gastroenteropancreatic neuroendocrine tumors, prostate cancer, leptomeningeal carcinomatosis due to breast cancer brain metastases, hereditary transthyretin amyloidosis, atherosclerotic cardiovascular diseases, severe hypertriglyceridemia, hereditary angioedema, acute hepatic porphyria, and more.

The next-generation drug conjugates market research report is one of a series of new reports that provides next-generation drug conjugates market statistics, including the next-generation drug conjugates industry's global market size, regional shares, competitors with a next-generation drug conjugates market share, detailed next-generation drug conjugates market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation drug conjugates industry. This next-generation drug conjugates market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The next-generation drug conjugates market consists of revenues earned by entities by providing services such as targeted cancer therapies, gene therapy conjugates, and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation drug conjugates market also includes sales of small molecule drug conjugates, RNA-targeted conjugates, and enzyme-linked drug conjugates. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.